AGRX — Agile Therapeutics Share Price
Last Trade - 00:00- $88.60m
- $73.52m
- $2.05m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.75 | 10.08 | 60.27 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agile Therapeutics, Inc. is a women’s healthcare company. The Company’s approved product, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch. Twirla uses its transdermal patch technology called Skinfusion. Skinfusion is designed to allow drug delivery through the skin while optimizing patch adhesion and patient comfort and wearability, which may help support compliance. Its product pipeline consists of two types of product candidates: Twirla line extensions and other transdermal contraceptive product candidates. These potential product candidates are designed to address market needs of additional non-daily contraceptive options. Its Twirla line extensions include AG200-15 Extended Regimen (ER), AG200-15 SmP, AG200-15 ER SmP, and AG890, a P-only contraceptive patch.
Directors
- Alfred Altomari CHM (62)
- Dennis Reilly (62)
- Geoffrey Gilmore (55)
- Robert Conway SVP (64)
- Paul Korner (55)
- Seth Fischer LED (65)
- Sharon Barbari (66)
- Sandra Carson (67)
- John Hubbard IND (64)
- Ajit Shetty (74)
- James Tursi IND (55)
- Last Annual
- December 31st, 2020
- Last Interim
- June 30th, 2021
- Incorporated
- December 5th, 1997
- Public Since
- May 22nd, 2014
- No. of Shareholders
- 23
- No. of Employees
- 28
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 92,999,964
- Address
- 101 Poor Farm Rd, PRINCETON, 08540-1941
- Web
- https://www.agiletherapeutics.com/
- Phone
- +1 6096831880
- Contact
- Matthew Riley
- Auditors
- Ernst & Young LLP
Latest News for AGRX
Upcoming events for AGRX
Q3 2021 Agile Therapeutics Inc Earnings Release
Similar to AGRX
180 LIFE SCIENCES ORD
NASDAQ Capital Market
9 METERS BIOPHARMA ORD
NASDAQ Capital Market
ABVC BIOPHARMA ORD
NASDAQ Capital Market
ACER THERAPEUTICS ORD
NASDAQ Capital Market
ADIAL PHARMACEUTICALS ORD
NASDAQ Capital Market
FAQ
As of Today at 19:58 UTC, shares in Agile Therapeutics are trading at $0.95. This share price information is delayed by 15 minutes.
Shares in Agile Therapeutics last closed at $0.95 and the price had moved by -66.8% over the past 365 days. In terms of relative price strength the Agile Therapeutics share price has underperformed the S&P500 Index by -74.82% over the past year.
The overall consensus recommendation for Agile Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Agile Therapeutics does not currently pay a dividend.
Agile Therapeutics does not currently pay a dividend.
Agile Therapeutics does not currently pay a dividend.
To buy shares in Agile Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.95, shares in Agile Therapeutics had a market capitalisation of $88.60m.
Here are the trading details for Agile Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AGRX
Based on an overall assessment of its quality, value and momentum Agile Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Agile Therapeutics is $5.00. That is 424.82% above the last closing price of $0.95.
Analysts covering Agile Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.76 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agile Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -74.76%.
As of the last closing price of $0.95, shares in Agile Therapeutics were trading -55.89% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Agile Therapeutics.
Agile Therapeutics' management team is headed by:
- Alfred Altomari - CHM
- Dennis Reilly -
- Geoffrey Gilmore -
- Robert Conway - SVP
- Paul Korner -
- Seth Fischer - LED
- Sharon Barbari -
- Sandra Carson -
- John Hubbard - IND
- Ajit Shetty -
- James Tursi - IND
We do not have data on Agile Therapeutics' shareholders